Focus: Medicure is a public biotechnology company focused on small-molecule therapeutics in cardiovascular, nephrology, and metabolic disease areas. The company operates with a highly concentrated revenue model dependent on a single marketed product.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Medicure to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Medicure's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Only marketed product and sole revenue source; statin with $4M annual Part D spending currently at peak of product lifecycle.
Help build intelligence for Medicure
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loss of exclusivity approaching; clinical data exists but patent expiration timeline undefined.
Duplicate entry in portfolio; indicates tirofiban portfolio complexity across multiple indications facing LOE.
Medicure Stock Drops 6.47% as Wider Loss and Drug Pricing Pressure Weigh on TSXV:MPH - kalkine.ca
Medicure Stock Drops 6.47% as Wider Loss and Drug Pricing Pressure Weigh on TSXV:MPH kalkine.ca
Earnings call transcript: Medicure posts higher revenue in Q2 2026 as loss widens - Investing.com
Earnings call transcript: Medicure posts higher revenue in Q2 2026 as loss widens Investing.com
Medicure Stock Climbs 6.25% as Pharmacy Growth and Rare-Disease Pipeline Support Bullish Momentum - kalkine.ca
Medicure Stock Climbs 6.25% as Pharmacy Growth and Rare-Disease Pipeline Support Bullish Momentum kalkine.ca
Medicure Inc. (TSXV:MPH) Shares Decline as Pharmaceutical Execution Risks and Investor Caution Pressure Sentiment - kalkine.ca
Medicure Inc. (TSXV:MPH) Shares Decline as Pharmaceutical Execution Risks and Investor Caution Pressure Sentiment kalkine.ca
Piramal Pharma - Positive Breakout: These 14 stocks cross above their 200 DMAs - The Economic Times
Piramal Pharma - Positive Breakout: These 14 stocks cross above their 200 DMAs The Economic Times
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight - PR Newswire UK
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight PR Newswire UK
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion.
Psychological First Aid by AI: Proof-of-Concept and Comparative Performance of ChatGPT-4 and Gemini in Different Disaster Scenarios.
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo